Nanovaccine
An antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
A Nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
Genetically engineered cell membrane nanovesicle that integrates antigen self-
presentation and immunosuppression reversal (ASPIRE) for cancer immunotherapy.
ASPIRE Nanovaccine
is derived from recombinant adenovirus-infected dendritic cells
- Peptide major histocompatibility complex class I (pMHC-I)
- Anti-PD1 Antibody
- B7 co-stimulatory molecules
These are simultaneously anchored by a programmed process
ASPIRE known as
Antigen Self-Presentation
&
immunosuppression
Reversal
To generate
broad-spectrum T-cell responses
that eliminate established tumours.
This platform technology not only allows for effective personalized cancer
immunotherapy but is also generally applicable to treat other diseases
Chronic viral infection, where T-cell exhaustion often occurs
during infection and prevents the optimal viral control
during infection and prevents the optimal viral control